Sino Biopharmaceutical company profile

1177 · HKEX · HKD

Compare Sino Biopharmaceutical
$5.11Change from previous close: −4.85%Absolute change: −$0.26

Close · November 20, 2026

Company profile

Sino Biopharmaceutical has 22,838 employees and is headquartered in Wan Chai, Hong Kong.

Based in Wan Chai, Hong Kong, and incorporated in 2000, Sino Biopharmaceutical Limited is an investment holding company whose operations centre on the research, development and sale of pharmaceuticals in the People's Republic of China. The group reports through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. Its oncology range includes anlotinib hydrochloride capsules under the Focus V brand, penpulimab injection under Annike and zongertinib tablets under Hernexeos, alongside liver disease treatments such as Tianqing Ganmei and Runzhong products, respiratory medicines and surgery and analgesia drugs. The company also holds long-term investments and runs a healthcare and hospital business.

In the fiscal year ended December 2025, the company recorded revenue of CNY 31.8 billion, up 10.3% from the previous year, and a net profit of CNY 2.3 billion. It had 22,838 employees, and its headquarters are in Wan Chai, Hong Kong.

Company facts

Industry
Biotechnology
Headquarters
Unit 09, Office Tower, Wan Chai
Employees
22,838
Chief executive
S. Y. Tse
Founded
2000
Fiscal year
January - December
Listing
1177 · HKEX
Indices
Hang Seng
Currency
HKD
ISIN
KYG8167W1380

Sino Biopharmaceutical and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Sino Biopharmaceutical1177Hong Kong SAR China$11.65B22,83828.2%34.2
Pharmaron Beijing300759China$10.59B25,08814.0%39.3
Sichuan Kelun-Biotech Biopharmaceutical6990Hong Kong SAR China$12.15B2,300-0.2%—
ALTEOGEN196170South Korea$9.05B18147.2%97.1
Haisco Pharmaceutical Group002653China$8.97B5,59721.1%44.1
Genscript Biotech1548Hong Kong SAR China$8.77B6,13514.9%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Sino Biopharmaceutical with its competitors